Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2009

01-03-2009 | Original Article

Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding β2-microglobulin genes

Authors: Chin-Hsuan Hsieh, Ya-Jan Hsu, Chien-Chung Chang, Hsin-Chun Liu, Kun-Lung Chuang, Cheng-Keng Chuang, See-Tong Pang, Kenichiro Hasumi, Soldano Ferrone, Shuen-Kuei Liao

Published in: Cancer Immunology, Immunotherapy | Issue 3/2009

Login to get access

Abstract

In renal cell carcinoma (RCC), HLA class I downregulation has been found in about 40% of the lesions examined. Since only scanty information is available about the molecular basis of these defects, we have investigated the mechanism(s) underlying HLA class I antigen downregulation or loss in six RCC cell lines. Five of them express HLA class I antigens although at various levels; on the other hand, HLA class I antigens are not detectable on the remaining cell line, the RCC52 cell line, belonging to a sarcomatoid subtype, even following incubation with IFN-γ. β2-microglobulin (β2 m) was not detected in RCC52 cells. Surprisingly, RCC52 cells harbor two mutations in the β 2 m genes in exon 1: a single G deletion (delG) in codon 6, which introduces a premature stop at codon 7, and a CT dinucleotide deletion (delCT), which leads to a premature stop at codon 55. Analysis of eight clonal sublines isolated from the RCC52 cell line showed that the two β 2 m gene mutations are carried separately by RCC52 cell subpopulations. The delG/delCT double mutations were detected in two sublines with a fibroblast-like morphology, while the delCT mutation was detected in the remaining six sublines with an epithelial cell morphology. Furthermore, loss of heterozygosity (LOH) of the β 2 m gene at STR D15S-209 was found only in the epithelioid subpopulation, indicating loss of one copy of chromosome 15. Immunostaining results of the tumor lesion from which the cell line RCC52 was originated were consistent with the phenotyping/molecular findings of the cultured cells. This is the first example of the coexistence of distinct β 2 m defects in two different tumor subpopulations of a RCC, where loss of one copy of chromosome 15 occurs in one of the subpopulations with total HLA class I antigen loss.
Literature
1.
go back to reference Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346–355PubMedCrossRef Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195:346–355PubMedCrossRef
2.
go back to reference Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171:885–889PubMedCrossRef Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171:885–889PubMedCrossRef
3.
go back to reference Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487–494PubMedCrossRef Ferrone S, Marincola FM (1995) Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487–494PubMedCrossRef
4.
go back to reference Fisher B, Fisher ER (1966) The interrelationship of hematogenous and lymphatic tumor cell dissemination: an experimental study. Rev Inst Nac Cancerol (Mex) 19:576–581 Fisher B, Fisher ER (1966) The interrelationship of hematogenous and lymphatic tumor cell dissemination: an experimental study. Rev Inst Nac Cancerol (Mex) 19:576–581
5.
go back to reference Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670PubMedCrossRef Cochran AJ, Huang RR, Lee J, Itakura E, Leong SP, Essner R (2006) Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6:659–670PubMedCrossRef
6.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153–156PubMedCrossRef
7.
go back to reference Cancer registry annual report 2002, Republic of China (Taiwan). Department of Health, Taipei, The executive Yuan, Republic of China, 2005 Cancer registry annual report 2002, Republic of China (Taiwan). Department of Health, Taipei, The executive Yuan, Republic of China, 2005
8.
go back to reference Dekernion JB (1993) Renal tumors. In: Walsh PC, Gittesm RF, Perlmutter AD, Stamey TA (eds) Campbell’s Urology, 6th edn edn. WB Saunders, Philadelphia, pp 1294–1342 Dekernion JB (1993) Renal tumors. In: Walsh PC, Gittesm RF, Perlmutter AD, Stamey TA (eds) Campbell’s Urology, 6th edn edn. WB Saunders, Philadelphia, pp 1294–1342
9.
go back to reference Uzzo RG, Novick AC, Bukowski RM, Finke JH (2000) Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukoowski RM, Novick AC (eds) Renal cell carcinoma. Molecular biology, Immunology and clinical management. Humana Press, Yotowa, pp 63–78CrossRef Uzzo RG, Novick AC, Bukowski RM, Finke JH (2000) Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukoowski RM, Novick AC (eds) Renal cell carcinoma. Molecular biology, Immunology and clinical management. Humana Press, Yotowa, pp 63–78CrossRef
10.
go back to reference Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M (1991) Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372–6380PubMed Cordon-Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M (1991) Expression of HLA-A, B, C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51:6372–6380PubMed
11.
go back to reference Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, Alexander RB (1995) Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol 17:222–228PubMed Jakobsen MK, Restifo NP, Cohen PA, Marincola FM, Cheshire LB, Linehan WM, Rosenberg SA, Alexander RB (1995) Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol 17:222–228PubMed
12.
go back to reference Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal carcinoma. J Urol 177:1269–1272PubMedCrossRef Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T (2007) Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal carcinoma. J Urol 177:1269–1272PubMedCrossRef
13.
go back to reference Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F (2006) Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 68:303–310PubMedCrossRef Romero JM, Aptsiauri N, Vazquez F, Cozar JM, Canton J, Cabrera T, Tallada M, Garrido F, Ruiz-Cabello F (2006) Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. Tissue Antigens 68:303–310PubMedCrossRef
14.
go back to reference Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, Huang DP (2002) Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 1590:150–158PubMedCrossRef Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, Huang DP (2002) Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 1590:150–158PubMedCrossRef
15.
go back to reference Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14:9–20PubMedCrossRef Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A (1978) Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14:9–20PubMedCrossRef
16.
go back to reference Redman CW, McMichael AJ, Stirrat GM, Sunderland CA, Ting A (1984) Class 1 major histocompatibility complex antigens on human extra-villous trophoblast. Immunology 52:457–468PubMed Redman CW, McMichael AJ, Stirrat GM, Sunderland CA, Ting A (1984) Class 1 major histocompatibility complex antigens on human extra-villous trophoblast. Immunology 52:457–468PubMed
17.
go back to reference Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918–1926PubMed Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) β2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171:1918–1926PubMed
18.
go back to reference Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306PubMed Stam NJ, Spits H, Ploegh HL (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137:2299–2306PubMed
19.
go back to reference Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177–188PubMedCrossRef Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35:177–188PubMedCrossRef
20.
go back to reference Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and β2-microglobulin on human neuroblastoma cell lines. J Immunol 130:2471–2478PubMed Lampson LA, Fisher CA, Whelan JP (1983) Striking paucity of HLA-A, B, C and β2-microglobulin on human neuroblastoma cell lines. J Immunol 130:2471–2478PubMed
21.
go back to reference Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66:185–194PubMedCrossRef Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66:185–194PubMedCrossRef
22.
go back to reference Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299:139–151PubMedCrossRef Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299:139–151PubMedCrossRef
23.
go back to reference Ogino T, Wang X, Ferrone S (2003) Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 278:33–44PubMedCrossRef Ogino T, Wang X, Ferrone S (2003) Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods 278:33–44PubMedCrossRef
24.
go back to reference Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F (2000) Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 55:443–448PubMedCrossRef Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F (2000) Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 55:443–448PubMedCrossRef
25.
go back to reference Goodfellow PN, Jones EA, Van Heyningen V, Solomon E, Bobrow M, Miggiano V, Bodmer WF (1975) The β2-microglobulin gene is on chromosome 15 and not in the HLA-region. Nature 254:267–269PubMedCrossRef Goodfellow PN, Jones EA, Van Heyningen V, Solomon E, Bobrow M, Miggiano V, Bodmer WF (1975) The β2-microglobulin gene is on chromosome 15 and not in the HLA-region. Nature 254:267–269PubMedCrossRef
26.
go back to reference Sugita M, Brenner MB (1994) An unstable β2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med 180:2163–2171PubMedCrossRef Sugita M, Brenner MB (1994) An unstable β2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med 180:2163–2171PubMedCrossRef
27.
go back to reference Xue C, Plieth D, Venkov C, Xu C, Neilson EG (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394PubMed Xue C, Plieth D, Venkov C, Xu C, Neilson EG (2003) The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63:3386–3394PubMed
28.
go back to reference Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65:5991–5995PubMedCrossRef Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65:5991–5995PubMedCrossRef
29.
go back to reference Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2-microglobilin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61:211–219PubMedCrossRef Cabrera CM, Jiménez P, Cabrera T, Esparza C, Ruiz-Cabello F, Garrido F (2003) Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2-microglobilin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens 61:211–219PubMedCrossRef
30.
go back to reference Pérez B, Benitez R, Fernández MA, Oliva MR, Soto JL, Serrano S, López Nevot MA, Garrido F (1999) A new β2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569–572PubMedCrossRef Pérez B, Benitez R, Fernández MA, Oliva MR, Soto JL, Serrano S, López Nevot MA, Garrido F (1999) A new β2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53:569–572PubMedCrossRef
31.
go back to reference Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13PubMedCrossRef Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3–13PubMedCrossRef
32.
go back to reference Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot β2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462–1471PubMed Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot β2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol 174:1462–1471PubMed
33.
go back to reference Kuroda N, Toi M, Hiroi M, Enzan H (2003) Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 18:551–555PubMed Kuroda N, Toi M, Hiroi M, Enzan H (2003) Review of sarcomatoid renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol 18:551–555PubMed
34.
go back to reference Harris SC, Hird PM, Shortland JR (1989) Immunohistochemistry and lectin histochemistry in sarcomatoid renal cell carcinoma: a comparison with classical renal cell carcinoma. Histopathology 15:607–616PubMedCrossRef Harris SC, Hird PM, Shortland JR (1989) Immunohistochemistry and lectin histochemistry in sarcomatoid renal cell carcinoma: a comparison with classical renal cell carcinoma. Histopathology 15:607–616PubMedCrossRef
35.
go back to reference Tomera KM, Farrow GM, Lieber MM (1983) Sarcomatoid renal carcinoma. J Urol 130:657–659PubMed Tomera KM, Farrow GM, Lieber MM (1983) Sarcomatoid renal carcinoma. J Urol 130:657–659PubMed
36.
go back to reference Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94:412–418PubMedCrossRef Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG (2004) Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int 94:412–418PubMedCrossRef
37.
go back to reference Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127–2133PubMed Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J (2003) Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 63:2127–2133PubMed
38.
go back to reference Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG (2007) Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56:117–128PubMedCrossRef Gouttefangeas C, Stenzl A, Stevanović S, Rammensee HG (2007) Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56:117–128PubMedCrossRef
Metadata
Title
Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding β2-microglobulin genes
Authors
Chin-Hsuan Hsieh
Ya-Jan Hsu
Chien-Chung Chang
Hsin-Chun Liu
Kun-Lung Chuang
Cheng-Keng Chuang
See-Tong Pang
Kenichiro Hasumi
Soldano Ferrone
Shuen-Kuei Liao
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-008-0565-7

Other articles of this Issue 3/2009

Cancer Immunology, Immunotherapy 3/2009 Go to the issue

Short Communication

p27 and salivary cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine